Christina Kalderén presents at the IPF Summit September 19-21st
Christina Kalderén, Oxcia’s Preclinical Director, will be speaking at the 7th IPF Summit on developing Oxcias first in class OGG1 inhibitor, OXC-201 for treatment of idiopathic pulmonary fibrosis (IPF):
-Harnessing a combination of in vivo and in vitro models to assess the therapeutic efficacy and create an efficient preclinical package
-Exploring patient-derived ex vivo model to identify finger print biomarkers.
Find out more about the meeting and join Christina to connect with the IPF community sharing cross-industry insights to bring effective therapies to patients faster: https://ter.li/IPFagenda
About OXC-201
OXC-201 is a small molecule inhibitor of OGG1, a potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), other fibrotic conditions and inflammatory diseases. By targeting the DNA repair enzyme OGG1 (8-oxo guanine DNA glycosylase-1), OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription. OGG1 plays a significant role in modulating inflammation and fibrogenesis; genetic downregulation or chemical inhibition of OGG1 has been shown to protect against inflammation and fibrosis in several experimental disease models. OXC-201 is patent protected and Oxcia AB has exclusive rights under the patent to develop and commercialize OXC-201.
The EIC (European Innovation Council) has awarded Oxcia AB a grant of 2.5 million euros within the EIC-Transition program which finances the next phase of the development of OXC-201.
If you are at the meeting and are interested in OXC-201, do not miss the opportunity to meet up with Christina.